🔴 SeaStar Medical is trading 12.3% down — no specific negative catalyst identified

SeaStar Medical is trading at $1.92, down 12.33%, with no specific negative catalyst identified in available reporting.

• On November 3, 2026, the FDA confirmed SeaStar Medical fulfilled QUELIMMUNE’s post-approval study requirements, allowing hospitals to use the therapy without the registry’s research infrastructure.
• The FDA news was positive and does not clearly explain the sharp decline; mixed broader-market moves do not establish a market-driven cause.